{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-055912","form_type":"8-K","ticker":"MASS","cik":"0001555279","company_name":"908 Devices Inc.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.459841+00:00","generated_at":"2026-05-14T22:37:59.923884+00:00","sec_items":["1.01","2.01","2.02","3.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"908 Devices Q1 rev +14% to $13.4M, raises FY26 outlook; buys NIRLAB for $15M","bullets":["Q1 revenue $13.4M (+14% YoY); recurring revenue $4.0M (30% of total); gross margin 51%, adj. 57%.","Net loss from cont. ops $12.0M; adj. EBITDA loss $2.5M vs $4.6M loss a year ago; cash $111.7M, no debt.","FY2026 revenue guidance raised to $67-70M (19-25% growth); installed base 3,903 devices (+23% YoY).","Completed acquisition of NIRLAB AG for $15M ($13M cash + $2M stock) plus up to $8M earn-out in stock.","NIRLAB adds NIR spectroscopy for narcotics; over 1M analyses; expands international and subscription revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-055912","json":"https://secwatch.observer/filing/0001104659-26-055912.json","markdown":"https://secwatch.observer/filing/0001104659-26-055912.md","text":"https://secwatch.observer/filing/0001104659-26-055912.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1555279/000110465926055912/0001104659-26-055912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1555279/000110465926055912/tm2613572d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:37:59.923884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b6255d3db8538b7cb73ec334e50651096c083c4","claim":"908 Devices Inc. reported first quarter and three months ended March 31, 2026 results: revenue $13.4 million, net income Net loss attributable to common stockholders was $12.0 million. Guidance raised.","evidence_excerpt":"subscriptions. This transaction reflects our focus on disciplined growth investments as we continue to execute our transformation strategy.” Recent Highlights · Revenue of $13.4 million for the first quarter of 2026, increasing 14% year over year · Recurring revenue was $4.0 million, representing 30% of total revenues for the quarter · Gross margin was 51% and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555279/000110465926055912/0001104659-26-055912-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter and three months ended March 31, 2026"},{"label":"Revenue","value":"$13.4 million"},{"label":"Net income","value":"Net loss attributable to common stockholders was $12.0 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d7dd73a4ed46aff603d2c219a8f21d184b133316","claim":"908 Devices Inc. completed an acquisition involving Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod for headline price of $15,000,000 (closed 2026-05-04).","evidence_excerpt":"and outstanding NIRLAB Shares in exchange for a preliminary consideration (the “Preliminary Consideration”) payable by the Company on the Closing Date with a headline price of $15,000,000 (the “Transaction”), comprised of (x) $13,000,000 in cash (the “Cash Consideration”) and (y) 293,368 shares of common stock of the Company, par value $0.001 per share (each such","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555279/000110465926055912/0001104659-26-055912-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod"},{"label":"Consideration","value":"headline price of $15,000,000"},{"label":"Closing","value":"2026-05-04"}],"fact_type":"ma_transaction"},{"claim_id":"ad7306082519d0e960e944c0c26abcbcbdd80671","claim":"908 Devices Inc. entered into Share Purchase Agreement with Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod valued at headline price of $15,000,000 (effective 2026-05-04).","evidence_excerpt":"On May 4, 2026 (the “Closing Date”), 908 Devices Inc. (the “Company”) completed its acquisition of NIRLAB SA, a corporation organized under the laws of Switzerland (“NIRLAB”), and its wholly owned subsidiary, NIRLAB Forensics Sàrl, a limited liability company organized under the laws of Switzerland (the “Subsidiary” and, together with NIRLAB, the “NIRLAB Group”), pursuant to a Share Purchase Agreement (the “Purchase Agreement”) with Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod (each a “Seller” and collectively, the “Sellers”) and NIRLAB.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555279/000110465926055912/0001104659-26-055912-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod"},{"label":"Value","value":"headline price of $15,000,000"},{"label":"Effective","value":"2026-05-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}